What is Cognex (tacrine)?
Cholinesterase inhibitors block the action of acetylcholinesterase, the enzyme responsible for the destruction of acetylcholine. Acetylcholine is one of several neurotransmitters in the brain. Reduced levels of acetylcholine in the brain are believed to be responsible for some of the symptoms of Alzheimer’s disease.
By blocking the enzyme that destroys acetylcholine, Cognex increases the concentration of acetylcholine in the brain, and this increase is believed to be responsible for the improvement in thinking seen with tacrine. The brand name Cognex is discontinued in the U.S.
Common side effects of Cognex include:
Serious side effects of Cognex include:
- increases in a liver test called alanine aminotransferase (ALT) as a result of liver damage.
- When a patient starts taking Cognex, blood is drawn on a weekly basis to measure ALT.
Unlike donezepril, Cognex does not reduce the elimination of other drugs, increasing their levels in blood and the likelihood of their side effects.
Animal reproduction studies have not been done with Cognex. It is unknown if Cognex causes fetal harm when taken by a pregnant woman.
What are the important side effects of Cognex (tacrine)?
The most common side effect of tacrine is an increase in a liver test called alanine aminotransferase (ALT) as a result of liver damage. When a patient starts taking tacrine, blood is drawn on a weekly basis to measure ALT. If there is an increase in blood ALT, the dosage of tacrine can be reduced. Other side effects of tacrine include:
Cognex (tacrine) side effects list for healthcare professionals
Common Adverse Events Leading to Discontinuation
In clinical trials, approximately 17% of the 2706 patients who received Cognex (tacrine) and 5% of the 1886 patients who received placebo withdrew permanently because of adverse events. It should be noted that some of the placebo-treated patients were exposed to Cognex (tacrine) prior to receiving placebo due to the variety of study designs used, including crossover studies.
Transaminase elevations were the most common reason for withdrawals during Cognex (tacrine) treatment (8% of all Cognex (tacrine) -treated patients, or 212 of 456 patients withdrawn). The controlled clinical trial protocols required that any patient with an ALT/SGPT elevation > 3 X ULN be withdrawn, because of concern about potential hepatotoxicity. Apart from withdrawals due to transaminase elevations, 244 patients (9%) withdrew for adverse events while receiving Cognex (tacrine) .
Other adverse events that most frequently led to the withdrawal of tacrine-treated patients in clinical trials were:
These adverse events also most frequently led to the withdrawal of placebo-treated patients, although at lower frequencies (0.1% to 0.2%).
Most Frequent Adverse Clinical Events Seen in Association With the Use of Tacrine
The events identified here are those that occurred at an absolute incidence of at least 5% of patients treated with Cognex (tacrine), and at a rate at least 2-fold higher in patients treated with Cognex (tacrine) than placebo.
The most common adverse events associated with the use of Cognex (tacrine) were:
Of these events, nausea and/or vomiting, diarrhea, dyspepsia, and anorexia appeared to be dose-dependent.
Adverse Events Reported in Controlled Trials
The events cited in the tables below reflect experience gained under closely monitored conditions of clinical trials with a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.
Table 3 lists treatment-emergent signs and symptoms that occurred in at least 2% of patients with Alzheimer's disease in placebo-controlled trials and who received the recommended regimen for dose introduction and titration of Cognex.
Table 3. Adverse Events Occurring in at Least 2% of Patients Receiving Cognex (tacrine) at a Starting Dose of 40 mg/day with Titration in 40 mg/day Increments Every 6 Weeks in Controlled Clinical Trials [Number (%) of Patients]
N = 634
N = 342
|Elevated Transaminasea||184 (29)||5 (2)|
|BODY AS A WHOLE|
|Headache||67 (11)||52 (15)|
|Fatigue||26 (4)||9 (3)|
|Chest Pain||24 (4)||18 (5)|
|Weight Decrease||21 (3)||4 (1)|
|Back Pain||15 (2)||14 (4)|
|Asthenia||15 (2)||7 (2)|
|Nausea and/or Vomiting||178 (28)||29 (9)|
|Diarrhea||99 (16)||18 (5)|
|Dyspepsia||57 (9)||22 (6)|
|Anorexia||54 (9)||11 (3)|
|Abdominal Pain||48 (8)||24 (7)|
|Flatulence||22 (4)||5 (2)|
|Constipation||24 (4)||8 (2)|
|HEMIC AND LYMPHATIC SYSTEM|
|Purpura||15 (2)||8 (2)|
|Myalgia||54 (9)||18 (5)|
|Dizziness||73 (12)||39 (11)|
|Confusion||42 (7)||24 (7)|
|Ataxia||36 (6)||12 (4)|
|Insomnia||37 (6)||18 (5)|
|Somnolence||22 (4)||11 (3)|
|Tremor||14 (2)||2 (<1)|
|Agitation||43 (7)||30 (9)|
|Depression||22 (4)||14 (4)|
|Thinking Abnormal||17 (3)||14 (4)|
|Anxiety||16 (3)||7 (2)|
|Hallucination||15 (2)||12 (4)|
|Hostility||15 (2)||5 (2)|
|Rhinitis||51 (8)||22 (6)|
|Upper Respiratory Infection||18 (3)||11 (3)|
|Coughing||17 (3)||18 (5)|
|SKIN AND APPENDAGES|
|Rashb||46 (7)||18 (5)|
|Facial Flushing, Skin Flushing||16 (3)||3 (<1)|
|Urination Frequency||21 (3)||12 (4)|
|Urinary Tract Infection||21 (3)||20 (6)|
|Urinary Incontinence||16 (3)||9 (3)|
|aALT or AST value of approximately 3 X ULN or greater orthat resulted in a change in patient management. Patients were monitored weekly.|
bIncludes COSTART terms: rash, rash-erythematous,rash-maculopapular, urticaria, petechialrash, rash-vesiculobullous, and pruritus.
Other Adverse Events Observed During All Clinical Trials
Cognex (tacrine) has been administered to 2706 individuals during clinical trials. A total of 1471 patients were treated for at least 3 months, 1137 for at least 6 months, and 773 for at least 1 year. Any untoward reactions that occurred during these trials were recorded as adverse events by the clinical investigators using terminology of their own choosing.
To provide a meaningful estimate of the proportion of individuals having similar types of events, the events were grouped into a smaller number of standardized categories using a modified COSTART dictionary. These categories are used in the listing below. The frequencies represent the proportion of the 2706 individuals exposed to Cognex (tacrine) who experienced that event while receiving Cognex (tacrine).
All adverse events are included except those already listed on the previous table and those COSTART terms too general to be informative. Events are further classified by body system categories and listed using the following definitions:
- frequent adverse events are defined as those occurring in at least 1/100 patients;
- infrequent adverse events are those occurring in 1/100 to 1/1000 patients; and
- rare adverse events are those occurring in less than 1/1000 patients. These adverse events are not necessarily related to Cognex (tacrine) treatment.
Only rare adverse events deemed to be potentially important are included.
Body As a Whole
Infrequent: Heart failure, myocardial infarction, angina pectoris, cerebrovascular accident, transient schemic attack, phlebitis, venous insufficiency, abdominal aortic aneurysm, atrial fibrillation or flutter, palpitation, tachycardia, bradycardia, pulmonary embolus, migraine, hypercholesterolemia.
Rare: Heart arrest, premature atrial contractions, A-V block, bundle branch block.
Infrequent: Glossitis, gingivitis, mouth or throat dry, stomatitis, increased salivation, dysphagia, esophagitis, gastritis, gastroenteritis, GI hemorrhage, stomach ulcer, hiatal hernia, hemorrhoids, stools bloody, diverticulitis, fecal impaction, fecal incontinence, hemorrhage (rectum), cholelithiasis, cholecystitis, increased appetite.
Rare: Duodenal ulcer, bowel obstruction.
Rare: Hyperthyroid, hypothyroid.
Hemic and Lymphatic
Infrequent: Dreaming abnormal, dysarthria, aphasia, amnesia, wandering, twitching, hypesthesia, delirium, paralysis, bradykinesia, movement disorder, cogwheel rigidity, paresis, neuritis, hemiplegia, Parkinson's disease, neuropathy, extrapyramidal syndrome, reflexes decreased/absent.
Infrequent: Apathy, increased libido, paranoia, neurosis.
Rare: Suicidal, psychosis, hysteria.
Rare: Hemoptysis, lung edema, lung cancer, acute epiglottitis.
Skin and Appendages
Frequent: Sweating increased.
Infrequent: Hematuria, renal stone, kidney infection, glycosuria, dysuria, polyuria, nocturia, pyuria, cystitis, urinary retention, urination urgency, vaginal hemorrhage, pruritus (genital), breast pain, impotence, prostate cancer.
Post introduction Reports
Voluntary reports of adverse events temporally associated with Cognex (tacrine) that have been received since market introduction, that are not listed above, and that may have no causal relationship with the drug include the following: pancreatitis, perforated peptic ulcer, and falling.
What drugs interact with Cognex (tacrine)?
Possible metabolic basis for interactions
Tacrine is primarily eliminated by hepatic metabolism via cytochrome P450 drug metabolizing enzymes. Drug-drug interactions may occur when Cognex (tacrine) is given concurrently with agents such as theophylline that undergo extensive metabolism via cytochrome P450 IA2.
Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approx-i mately 2-fold. Therefore, monitoring of plasma theophylline concentrations and appropriate reduction of theophylline dose are recommended in patients receiving tacrine and theophylline concurrently. The effect of theophylline on tacrine pharmacokinetics has not been assessed.
Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.
Because of its mechanism of action, Cognex (tacrine) has the potential to interfere with the activity of anticholinergic medications.
Cholinomimetics and Cholinesterase Inhibitors
A synergistic effect is expected when Cognex (tacrine) is given concurrently with succinylcholine, cholinesterase inhibitors, or cholinergic agonists such as bethanechol.
In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.
Rate and extent of tacrine absorption were not influenced by the coadministration of an antacid containing magnesium and aluminum. Tacrine had no major effect on digoxin or diazepam pharmacokinetics or the anticoagulant activity of warfarin.
Cognex (tacrine) is a cholinesterase inhibitor used to treat patients with mild to moderate dementia associated with Alzheimer’s disease. Common side effects of Cognex include nausea, indigestion, vomiting, diarrhea, abdominal pain, and skin rash. Serious side effects of Cognex include increases in a liver test called alanine aminotransferase (ALT) as a result of liver damage. When a patient starts taking Cognex, blood is drawn on a weekly basis to measure ALT. Animal reproduction studies have not been done with Cognex. It is unknown if Cognex causes fetal harm when taken by a pregnant woman. Cognex may pass into breast milk and be harmful to the nursing infant; it should not be used while breastfeeding.
Multimedia: Slideshows, Images & Quizzes
Alzheimers Disease Quiz: Stages, Symptoms & Signs
Take the Alzheimer's Quiz to discover some of the mysteries behind this cognitive disorder. Learn causes, symptoms, treatments,...
Picture of Vascular (Multi-Infarct) Dementia 2
There are several types of vascular dementia, which vary slightly in their causes and symptoms. See a picture of Vascular...
Picture of Lewy Body Dementia
Lewy body dementia (LBD) is one of the most common types of progressive dementia. See a picture of Lewy Body Dementia (LBD) and...
Picture of Frontotemporal Dementia (FTD)
Frontotemporal dementia, sometimes called frontal lobe dementia, describes a group of diseases characterized by degeneration of...
Picture of HIV-associated Dementia (HAD)
A 40-year-old woman diagnosed with HIV presented with confusion and decline in memory. See a picture of HIV-associated Dementia...
Picture of Alzheimer's Disease
In the early stages of Alzheimer's disease, patients may experience memory impairment, lapses of judgment, and subtle changes in...
Picture of Vascular (Multi-Infarct) Dementia 1
Vascular dementia is the second most common cause of dementia, after Alzheimer's disease. See a picture of Vascular...
Dementia, Alzheimer's Disease, and Aging Brains
What is dementia? Learn about dementia disorders such as Lewy Body Dementia, Alzheimer's disease (AD), Vascular (multi-infarct)...
Caring for Someone With Alzheimer's Disease
Use this guide for advice on caring for someone with Alzheimer's. Learn to spot early signs and symptoms of Alzheimer's disease...
Alzheimer's Disease Symptoms & Early Diagnosis
Learn the early warning signs and symptoms of Alzheimer's disease. Memory loss and confusion can be signs of normal aging, but...
Alzheimer's Diagnosis: Your Family's Questions Answered
Is there any difference between Alzheimer's disease and Dementia? Is Alzheimer's disease deadly? Find out the truth about...
Brain Health: Foods that May Lower Dementia Risk
What foods are associated with Alzheimer's disease and other forms of dementia? Cognitive function is predicated on good...
Dementia and Alzheimer's: 13 Bad Brain Health Habits
Good brain health depends on exercising regularly, eating well, and getting enough sleep. Learn how to develop good health habits...
Healthy Aging: Reasons for Memory Loss and Dementia Risk
Forget your keys? That might be absentmindedness. Forget what you did this morning? That might be a more serious memory problem....
Dementia and Alzheimer's: Is It Aging or Alzheimer's?
Learn the difference between memory problems that can happen to all of us as we get older and real warning signs of dementia.
Related Disease Conditions
Frontotemporal Dementia (Pick's Disease and Semantic Dementia)
Frontotemporal dementia (FTD) is a syndrome that is associated with shrinking of the frontal and temporal lobes of the brain. Frontotemporal dementia used to be referred to as Pick's disease. Frontotemporal dementia has a strong genetic component. Symptoms of frontotemporal dementia include changes in behavior or problems with language. There is no treatment that slows the progression of frontotemporal dementia. Medication may be prescribed to improve symptoms. The outcome for patient's with frontotemporal dementia is poor.
Dementia is defined as a significant loss of intellectual abilities such as memory capacity, severe enough to interfere with social or occupational functioning. There are several different types of dementia, including cortical, subcortical, progressive, primary, and secondary dementias. Other conditions and medication reactions can also cause dementia. Dementia is diagnosed based on a certain set of criteria. Treatment for dementia is generally focused on the symptoms of the disease.
Alzheimer's Disease: Financial Planning
Alzheimer's disease can be not only mentally devastating to an indivdiual and family, it can also be emotionally devastating. Preparing financially for someone with Alzheimer's disease is an important task to complete so that bills get paid and the best coverage is provided. Learn what Medicade and Medicare will provide for a patient.
Alzheimer's Disease Patient Caregiver Guide
Caring for a loved one or patient with Alzheimer's can become a difficult and overwhelming task at times. This guide helps caregivers of individual's with Alzheimer's deal with communicating, bathing, and dressing; as well as problem solving with incontinence, sleeping, wandering; and coping with difficulties Alzheimer's patients present.
Alzheimer's disease is a common cause of dementia. Symptoms and warning signs of Alzheimer's disease include memory loss, difficulty performing familiar tasks, disorientation to time and place, misplacing things, and more. The biggest risk factor for Alzheimer's disease is increased age. Treatment for Alzheimer's is often targeted toward decreasing the symptoms and progression of the disease.
7 Alzheimer's Disease Stages and Symptoms
The signs and symptoms of Alzheimer's disease depend on the stage of the disease. Some doctors and researchers disagree in regard to the number of stages of Alzheimer's disease (from 1 to 7 stages). The Global Deterioration Scale or GDS identifies seven stages of Alzheimer's disease that include stage 1 (no impairment), stage 2 (very mild cognitive decline), stage 3 (mild cognitive decline), stage 4 (moderate cognitive decline), stage 5 (moderately severe decline), stage 6 (severe decline), and stage 7 (very severe decline). There is no cure for Alzheimer's disease, however, there are drugs and therapies to help the symptoms Alzheimer's disease causes.
Lewy Body Dementia (Dementia with Lewy Bodies)
Lewy body dementia (LBD or dementia with Lewy bodies) is one the most common causes of dementia. There are two types of LBD: 1) dementia with Lewy bodies, and 2) Parkinson's disease dementia. Symptoms of LBD are changes in a person's ability to think, movement problems, and sleep disorders. Treatment of LBD includes lifestyle changes, management of symptoms, palliative care, and medications to manage symptoms.
Early Warning Signs and Stages of Dementia
Dementia is a decline and or loss of behavior of mental abilities, loss of judgment, language, and reasoning. Early warning signs of dementia include misplacing items, difficulty planning or problem solving, poor work performance, difficulty doing familiar tasks, and withdrawal from social activities. There are seven stages of dementia that range from stage 1, with no cognitive decline to stage 7, which is severe dementia.
Treatment & Diagnosis
- Alzheimers Disease FAQs
- Alzheimer's Disease - NSAID Protection?
- Alzheimer's Disease: Drug for Symptoms
- Dementia Prevention: Brain Exercise
- Caring for Someone with Alzheimer's
- Robin Williams and Lewy Body Dementia
- Lewy Body Dementia (LBD) Symptoms and Prognosis
- Gum Disease Linked to Alzheimer's Disease
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.